|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
National Center for Complementary and Alternative Medicine (NCCAM) |
| Information provided by: | National Center for Complementary and Alternative Medicine (NCCAM) |
| ClinicalTrials.gov Identifier: | NCT00067301 |
Purpose
The purpose of this study is to determine if omega-3 fatty acid EPA will enhance and speed up response to antidepressant therapy with Celexa (Citalopram) in people suffering from Major Depressive Disorder. All patients will receive Celexa, 50% will receive EPA, 50% placebo EPA.
| Condition | Intervention | Phase |
|
Major Depression |
Drug: Polyunsaturated Fatty Acids (PUFA) Drug: Citalopram |
Phase III |
| MedlinePlus related topics: | Antidepressants Depression |
| ChemIDplus related topics: | Escitalopram Benzetimide Citalopram Citalopram hydrobromide Dexetimide Escitalopram oxalate |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study |
| Official Title: | PUFA Augmentation in Treatment of Major Depression |
Eligibility
| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| United States, California | |||||
| Cedars-Sinai Medical Center Dept. of Psychiatry | |||||
| Los Angeles, California, United States, 90048 | |||||
| Principal Investigator: | Lev Gertsik, MD | Cedars-Sinai Medical Center |
More Information
| Study ID Numbers: | R21 AT001077, GertsikL |
| First Received: | August 14, 2003 |
| Last Updated: | January 23, 2008 |
| ClinicalTrials.gov Identifier: | NCT00067301 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|
|
|
|